ライフサイエンスコーパス: HPV vaccine

1 ain partial cross-protection by the bivalent HPV vaccine.

2 o timing and number of doses of quadrivalent HPV vaccine.

3 asurable preventable disease outcome for the HPV vaccine.

4 t a moderately high level of knowledge about HPV vaccine.

5 ; no deaths were deemed to be related to the HPV vaccine.

6 independently associated with not receiving HPV vaccine.

7 ditions were not less likely to initiate the HPV vaccine.

8 d men and the approval of a second, bivalent HPV vaccine.

9 idate combination preventive and therapeutic HPV vaccine.

10 eling the potential impact of a prophylactic HPV vaccine.

11 red to compose a broadly efficacious genital HPV vaccine.

12 ecimen, 36.9% reported receiving >=1 dose of HPV vaccine.

13 vaccine or one or two doses of a nonavalent HPV vaccine.

14 ion, defined as receiving at least 1 dose of HPV vaccine.

15 -.6]) for HPV types targeted by the 9-valent HPV vaccine.

16 nts occurred that were deemed related to the HPV vaccine.

17 t from prophylactic administration of the 9v HPV vaccine.

18 cipants, 704 (39.8%) self-reported receiving HPV vaccine.

19 CCs after the first dose of the quadrivalent HPV vaccine.

20 reported receipt of at least one dose of the HPV vaccine.

21 nts after administration of the quadrivalent HPV vaccine.

22 ed in the 4-valent and 9-valent prophylactic HPV vaccines.

23 forts are needed to realise the potential of HPV vaccines.

24 the quadrivalent and nonavalent prophylactic HPV vaccines.

25 HPV types than is achieved with the licensed HPV vaccines.

26 ases potentially preventable by prophylactic HPV vaccines.

27 f cervical cancer from the second-generation HPV vaccines.

28 to our understanding of the early impact of HPV vaccines.

29 types and the efficacy of current and future HPV vaccines.

30 s have implications for the design of future HPV vaccines.

31 rier to initiating the human papillomavirus (HPV) vaccine.

32 prophylactic bivalent human papillomavirus (HPV) vaccine.

33 drivalent and bivalent human papillomavirus (HPV) vaccines.

34 -16/18-positive, 136 (4%) received 1 dose of HPV vaccine, 108 (3%) received 2 doses, and 325 (10%) re

35 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

36 04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine eff

37 We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV

38 reviously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to as "addition

39 with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.

40 Among girls who received 2 doses of HPV vaccine 6 months apart, responses to HPV-16 and HPV-

41 However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain

42 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years who had

43 e data support vaccination with quadrivalent HPV vaccine across a broad range of baseline subject cha

44 Awareness of HPV vaccines across educational attainment ranged from 3

45 ation for prophylactic human papillomavirus (HPV) vaccines, adult women who remain at risk of cervica

46 Uptake of human papillomavirus (HPV) vaccine among girls in the Dutch immunization progr

47 oral HPV prevalence for 4 types targeted by HPV vaccine and 33 nonvaccine types in unvaccinated US a

48 Costa Rica Vaccine Trial; 3727 received the HPV vaccine and 3739 received the control vaccine.

49 of parents and health care providers toward HPV vaccine and critically evaluate controversial and ch

50 n 19 women who had received the quadrivalent HPV vaccine and in 538 women who had not received the va

51 against vaccine-type CIN2+ after 3 doses of HPV vaccine and lower but significant VE with 1 or 2 dos

52 The control group received HPV vaccine and was replaced with a new unvaccinated con

53 11-88x5 adjuvanted with alum or the licensed HPV vaccines and challenged intravaginally with HPV6, HP

54 items, not attending a school meeting about HPV vaccine, and not knowing anyone with cancer.

55 B2) sensitivities to cross-neutralization by HPV vaccine antibodies compared to that of the A1 sublin

56 tial of L2 as a second-generation preventive HPV vaccine antigen.

57 The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1

58 rly is decreasing and women who received the HPV vaccine are due to attend screening for the first ti

59 IMPORTANCE Licensed preventive HPV vaccines are composed of VLPs derived by expression

60 Human papillomavirus (HPV) vaccines are given as a two-dose schedule in childr

61 Human papillomavirus (HPV) vaccines are ideally administered before HPV exposu

62 Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention,

63 ccine and the marketed Human Papillomavirus (HPV) vaccines are prohibitively expensive.

64 Human papillomavirus (HPV) vaccines are recommended for girls prior to sexual

65 Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- o

66 All patients received HPV vaccine as an adjuvant treatment and were clinically

67 sent study supports the continued use of the HPV vaccine as an adjuvant treatment for recurrent respi

68 Additionally, the high long-term effect of HPV vaccine as an important cervical-cancer prevention t

69 mized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261) or 2 doses a

70 patient received 3 doses of the quadrivalent HPV vaccine at 0, 2, and 6 months in 2013, and both pati

71 In Mexico, HPV vaccines available immunize against genotypes 16/18

72 n was used to obtain prevalence estimates of HPV vaccine awareness and initiation adjusted for sociod

73 ently, there are three licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the

74 Safe and effective HBV and HPV vaccines, based on virus-like particles, are commerc

75 Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self

76 reported receipt of at least one dose of the HPV vaccine before the age of 26 years (29.2% in women a

77 ogenicity of a booster dose of both bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV).

78 HPV vaccine can be delivered with high coverage in schoo

79 s were randomly assigned (1:1) to receive an HPV vaccine (Cervarix, GlaxoSmithKline, Rixensart, Belgi

80 ent advances in screening and development of HPV vaccines, cervical cancer remains one of the deadlie

81 at 6 or 12 months in the group who received HPV vaccine compared with the control group.

82 rd arm, 55 of 161 (34.2%) girls received the HPV vaccine, compared with 28 of 160 (17.5%) girls in th

83 three FDA-approved multivalent prophylactic HPV vaccines composed of virus-like particles (VLPs).

84 The human papillomavirus (HPV) vaccines consist of major capsid protein (L1) virus

85 A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) w

86 erage globally by 2020 with a broad-spectrum HPV vaccine could avert 6.7-7.7 million cases in this pe

87 Availability of a human papillomavirus (HPV) vaccine could have an important public health impac

88 human papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adolescents has increased

89 HPV vaccine coverage was 84.7% for dose 1, 81.4% for dos

90 Among a population with relatively low HPV vaccine coverage, the PPV of cervical cytology for C

91 Our findings also suggested that 2 doses of HPV vaccine delivered at 0 and 12 months might afford si

92 nd January 2010) assessing 4 schedules of an HPV vaccine delivered in 21 schools to 903 adolescent gi

93 uscular injection of 3 doses of quadrivalent HPV vaccine delivered on a standard dosing schedule (at

94 sponse to quadrivalent human papillomavirus (HPV) vaccine delivered at 0, 2, and 6 months in young ad

95 ervical cancer worldwide and is the focus of HPV vaccine development efforts.

96 ed and therefore represent ideal targets for HPV vaccine development.

97 Vaccine effectiveness of at least 1 HPV vaccine dose at age <=18 years or >18 years was 59%

98 analysis, 809 girls who received at least 1 HPV vaccine dose had valid serum measurements 1 month af

99 348 (50.7%) self-reported ever receiving >=1 HPV vaccine dose; the median age at first HPV vaccinatio

100 onse following reduced human papillomavirus (HPV) vaccine doses has not been determined.

101 States completing the human papillomavirus (HPV) vaccine doubled.

102 gible patients' receipt of any valid dose of HPV vaccine during the study step.

103 round of HPV screening, possibly dampened by HPV vaccine effect; in this study, although the point es

104 We examined HPV vaccine effectiveness against HPV prevalence by numb

105 ived their first dose at age <=18, estimated HPV vaccine effectiveness was high regardless of number

106 Human papillomavirus (HPV) vaccine effectiveness and herd protection are not w

107 specified, end-of-study combined analysis of HPV vaccine efficacy studies for prevention of cervical

108 de studies of cervical precancer risk and of HPV vaccine efficacy.

109 of an HPV16/18 prevalence of 12% before the HPV vaccine era, extended catch-up vaccination for femal

110 dose to a two-dose protocol for the licensed HPV vaccines, especially in younger adolescents (aged 9-

111 ohort study revealed no increased risk among HPV vaccine-exposed girls, with incidence rate ratios cl

112 of clinically approved human papillomavirus (HPV) vaccines, Females United to Unilaterally Reduce End

113 im of assessing the efficacy of the bivalent HPV vaccine for preventing HPV 16/18-associated cervical

114 What is the potential of HPV vaccines for primary prevention?

115 recently approved the human papillomavirus (HPV) vaccine for individuals aged 27-45 years, the Cente

116 vaccine antigen in the human papillomavirus (HPV) vaccine Gardasil.

117 two doses or three doses of the quadrivalent HPV vaccine (Gardasil [Merck Sharp & Dohme, Whitehouse S

118 HPV vaccines generate functional (neutralizing) antibodi

119 ohort for years 0-4, and 2073 women from the HPV vaccine group and 2530 women from the new unvaccinat

120 2635 women in the HPV vaccine group and 2677 women in the control group we

121 0, 2009, and July 5, 2012, 2635 women in the HPV vaccine group and 2836 women in the new unvaccinated

122 tions at 6 months were 33.4% (82/248) in the HPV vaccine group and 31.6% (95/298) in the control grou

123 ates at 12 months were 48.8% (86/177) in the HPV vaccine group and 49.8% (110/220) in the control gro

124 unvaccinated control group and three in the HPV vaccine group died; no deaths were deemed to be rela

125 c 21, 2005, 7466 participants were enrolled (HPV vaccine group n=3727 and hepatitis A virus vaccine c

126 After the blinded phase, women in the HPV vaccine group were invited to enrol in the long-term

127 rol group and 201 [10%] of 2073 women in the HPV vaccine group).

128 The bivalent HPV vaccine has high efficacy against HPV 16/18-associat

129 A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men

130 herlands, the bivalent human papillomavirus (HPV) vaccine has been offered to preadolescent girls via

131 ing the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 d

132 Clinical trials on the viral-like particle HPV vaccines have good safety profiles and promising eff

133 Since preventative HPV vaccines have not been widely used in many countries

134 Both HPV vaccines have shown very good efficacy and safety.

135 alent and quadrivalent human papillomavirus (HPV) vaccines have been introduced in most developed cou

136 Although available human papillomavirus (HPV) vaccines have high efficacy against incident infect

137 Human papillomavirus (HPV) vaccines have the potential to prevent cervical can

138 ety concerns was observed among parents with HPV vaccine hesitancy, contrary to the nonserious and se

139 s method was applied to data on the 9-valent HPV vaccine (HPV9) to detect potential safety problems.

140 il cases reported that they would accept the HPV vaccine if it were offered again (97% and 93% respec

141 on the recent successes of immunotherapy and HPV vaccine immune prevention.

142 Quadrivalent HPV vaccine immunogenicity delivered on 3 alternative do

143 and adenocarcinoma in situ (CIN2+) from the HPV Vaccine Impact Monitoring Project (HPV-IMPACT), 2008

144 arcinoma in situ (designated CIN2+) from the HPV Vaccine Impact Monitoring Project (HPV-IMPACT; 2008-

145 age of HPV screen-positive women, monitoring HPV vaccine impact, and HPV testing in groups for which

146 rs of vaccine introduction, indicating early HPV vaccine impact.

147 ing HPV types in CIN2+ may be used to assess HPV vaccine impact.

148 understand real-world human papillomavirus (HPV) vaccine impact, continuous evaluation using populat

149 mmunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >3

150 S. vaccination policy on use of the 9-valent HPV vaccine in adult women and men is being reviewed.

151 A single dose of HPV vaccine in girls aged 9-14 years continues to provid

152 A single dose of the 2-valent or 9-valent HPV vaccine in girls aged 9-14 years induced robust immu

153 eness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States.

154 014, more than 57 countries had included the HPV vaccine in their national health programmes.

155 ist regarding the safety of the quadrivalent HPV vaccine in this context.

156 Clinical trials on HPV vaccines in persons living with HIV and particularly

157 females aged 16-17 years who got 1 of the 2 HPV vaccines in phase 3 licensure trials, virtually all

158 t recent evidence about the effectiveness of HPV vaccines in real-world settings and to quantify the

159 ction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls [DoRIS] trial), 930 Tanz

160 al to be used for monitoring of prophylactic HPV vaccines in the future.

161 Since licensure of the human papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adol

162 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent girls in India was converted

163 ss of the quadrivalent human papillomavirus (HPV) vaccine in preventing high-grade cervical lesions h

164 s for the quadrivalent human papillomavirus (HPV) vaccine in Tanzanian schoolgirls.

165 Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effec

166 f Cervarix or Gardasil human papillomavirus (HPV) vaccines in adults infected with the human immunode

167 Effectiveness of human papillomavirus (HPV) vaccines in the context of both guidelines, which r

168 the potential value of human papillomavirus (HPV) vaccines, information concerning the incidence and

169 nal research articles describing barriers to HPV vaccine initiation and completion among US adolescen

170 analysis, the effect of the intervention on HPV vaccine initiation and completion by race and ethnic

171 t (95% CI, 0.6%-6.2%) greater improvement in HPV vaccine initiation compared with adolescents in cont

172 morbidities; we estimated the prevalence of HPV vaccine initiation in cancer survivors versus the US

173 Conclusion HPV vaccine initiation rates in cancer survivors are low

174 th the human papillomavirus (HPV), yet their HPV vaccine initiation rates remain low.

175 ears postcompletion of therapy); we assessed HPV vaccine initiation, sociodemographic and clinical ch

176 ese data provide baseline information before HPV vaccine introduction.

177 The implementation of the HPV vaccine is a tremendous milestone in our effort towa

178 HPV vaccine is also recommended for MSM, people living w

179 Prophylactic HPV vaccine is available for primary prevention.

180 This study demonstrated the HPV vaccine is effective in a real-world setting of high

181 HPV vaccine is recommended routinely for 11- or 12-year-

182 In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinat

183 The bivalent human papillomavirus (HPV) vaccine is highly effective and induces robust sero

184 In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and

185 The quadrivalent human papillomavirus (HPV) vaccine is recommended for all girls and women 9 to

186 ratio and interviewed about cervical cancer, HPV vaccine knowledge and reasons why they might have re

187 A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types tar

188 nt virus-like particle human papillomavirus (HPV) vaccine (Merck, Rahway, NJ, USA; 0.5 mL intramuscul

189 iminary evidence suggests that recipients of HPV vaccines might derive prophylactic benefits from one

190 her the bivalent (n = 188) or the nonavalent HPV vaccine (n = 184).

191 P < .001); survivors were more likely to be HPV vaccine-naive than general population peers (odds ra

192 The introduction of HPV vaccines necessitates the estimation of the populati

193 perceived lack of insurance coverage for the HPV vaccine (odds ratio [OR], 4.0; 95% CI, 2.7 to 5.9; P

194 25 years, 84.4% reported having heard of the HPV vaccine; of these, 28.5% had initiated HPV vaccinati

195 cent girls in Vietnam, administration of the HPV vaccine on standard and alternative schedules was im

196 pact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related t

197 substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-related cervical disease i

198 o, to receive one or two doses of a bivalent HPV vaccine or one or two doses of a nonavalent HPV vacc

199 Women received quadrivalent HPV vaccine or placebo (1:1) at entry, week 4, and week

200 ts 9-26 years old randomized to quadrivalent HPV vaccine or placebo in phase 2/3 studies were analyze

201 ncertainty and low levels of knowledge about HPV vaccines or infection, exposure to negative informat

202 rs' perceived lack of insurance coverage for HPV vaccine (OR, 6.6; 95% CI, 3.9 to 11.0; P < .001), ma

203 6, 18, 31, 33, 45, 52, 58) in the nonavalent HPV vaccine, PHIV had significantly higher incidence (P

204 6, 18, 31, 33, 45, 52, 58) in the nonavalent HPV vaccine, PHIV had significantly higher incidence (p=

205 HPV vaccines prevent infection with HPV 16 and 18, which

206 Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 1

207 Decreasing human papillomavirus (HPV) vaccine prices makes scaling up of vaccination prog

208 Human papillomavirus (HPV) vaccine programs may decrease the morbidity and mor

209 Bivalent and quadrivalent HPV vaccines protect against 66% of HPV-associated cervi

210 Human papillomavirus (HPV) vaccines provide an opportunity to reduce the incid

211 A single dose of HPV vaccine provides similar protection against persiste

212 ence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dos

213 died the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasi

214 By preventing HPV infection, quadrivalent HPV vaccine (qHPV) reduces risk of anal cancer/precancer

215 bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV).

216 58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.

217 currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions

218 een after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associa

219 We conducted a case control study of HPV vaccine receivers and non-receivers within a phase I

220 Lack of provider HPV vaccine recommendation was reported by 73% (95% CI,

221 Lack of health care provider HPV vaccine recommendation was the outcome of interest i

222 reporting receipt of a health care provider HPV vaccine recommendation.

223 ong men who have sex with men (MSM); and (6) HPV vaccine recommendations.

224 objective was to show that the quadrivalent HPV vaccine reduced the incidence of external genital le

225 concentrations >/=29 months after 3 doses of HPV vaccine regardless of dose-timing, and extended sche

226 Adolescent uptake of human papillomavirus (HPV) vaccine remains low.

227 Recent developments in HPV vaccine research are reviewed.

228 He received the quadrivalent HPV vaccine resulting in clearance of all lesions after

229 A one-dose HPV vaccine schedule would be simpler and cheaper to del

230 onstrates long-term immunogenicity of the 2D HPV vaccine schedule.

231 eported their reasons for not initiating the HPV vaccine series in the 2015-2018 NIS.

232 as the primary reason for not initiating the HPV vaccine series increased from 13.0% (95% CI, 12.1%-1

233 and 75.1% initiated and 58.6% completed the HPV vaccine series.

234 3.5% of Texas adolescents have completed the HPV vaccine series.

235 he 3-dose quadrivalent human papillomavirus (HPV) vaccine series (HPV-6, -11, -16, -18) is immunogeni

236 The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe

237 equent among subjects receiving quadrivalent HPV vaccine than among those receiving placebo (57% vs.

238 Second-generation HPV vaccines that protect against additional oncogenic H

239 success stories such as the well-publicised HPV vaccine, the challenges remain significant.

240 Despite the availability of preventive HPV vaccines, their poor uptake leaves individuals at ri

241 ficacious prophylactic human papillomavirus (HPV) vaccine there is still a considerable global burden

242 no relationship to the 2009 introduction of HPV vaccine to Denmark's vaccination program.

243 Administration of HPV vaccine to HPV-naive women, and women who are alread

244 dle-free, and affordable formulations of the HPV vaccine to overcome the socioeconomic barriers assoc

245 es and concerns as barriers to providing the HPV vaccine to patients.

246 Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by c

247 ars old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis.

248 en (n=5,871) in the NCI-sponsored Costa Rica HPV Vaccine Trial's prevaccination enrollment visit were

249 HPV vaccine trials and epidemiologic studies based on vi

250 present thinking about primary endpoints for HPV vaccine trials as developed at an experts workshop c

251 rovide insights in future efforts, including HPV vaccine trials.

252 dently associated with seroprevalence of any HPV vaccine type among both females and males, and pover

253 12.2% among males; the seroprevalence of any HPV vaccine type increased with age, reaching 42.0% amon

254 ic blacks had a higher seroprevalence of any HPV vaccine type than that observed for non-Hispanic whi

255 For any HPV vaccine type, the seroprevalence was 32.5% among fem

256 patients developed 100-fold higher levels of HPV vaccine type-specific antibodies compared with the p

257 d with hrHPV types covered by the nonavalent HPV vaccine (type 16, 18, 31, 33, 45, 52, or 58).

258 nefit of vaccinating boys, and potential for HPV-vaccine-type elimination.

259 revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16, and 18, was

260 HPV vaccine types 6 and 11 (low-risk types) and 16 and 1

261 mory, suggesting possible protection against HPV vaccine types after a single dose of 4vHPV.

262 seropositivity rates were above 95% for all HPV vaccine types and all schedules, except HPV18, with

263 Between the 2 surveys, the prevalence of HPV vaccine types decreased from 8.3% to 1.4%, whereas t

264 However, the prevalence of HPV vaccine types was relatively low.

265 revalence, incidence, and clearance of 9v HR-HPV vaccine types, compared with other HR types, and ass

266 Among the 7 HPV vaccine types, HPV33 had the longest median duration

267 3%-69% were positive for >=1 of the 9-valent HPV vaccine types.

268 tion between 9-valent (9v) high-risk HPV (HR-HPV) vaccine types and abnormal cytology has not been we

269 HPV vaccine uptake falls short of national public health

270 We evaluated HPV vaccine uptake patterns over 2008-2011 by race/ethni

271 ack on their personal in-office success with HPV vaccine uptake via intra-campus mail.

272 to vaccination may help to increase overall HPV vaccine uptake.

273 6 years) = 1.34) were associated with higher HPV vaccine uptake.

274 2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screeni

275 the proportion of adolescents up to date for HPV vaccine using provider-verified vaccination data fro

276 hose who initiated the human papillomavirus (HPV) vaccine versus those who did not.

277 measured 1 month after the third dose of the HPV vaccine was administered; GMT was determined by type

278 In this study, 1 or 2 doses of quadrivalent HPV vaccine was associated with substantial protection a

279 The immunogenicity of quadrivalent HPV vaccine was comparable among subjects with differing

280 The bivalent HPV vaccine was efficacious in prevention of incident an

281 updated model, the bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases, 12 deaths,

282 er 1000 vaccinated girls, and the nonavalent HPV vaccine was estimated to avert 19 cases, 14 deaths,

283 Willingness to recommend the HPV vaccine was moderate, with 69.7% intentionally initi

284 tched analyses, exposure to the quadrivalent HPV vaccine was not associated with significantly higher

285 Clinician recommendation for the HPV vaccine was received by 81.4% of adolescents, and 75

286 The quadrivalent HPV vaccine was well tolerated by both patients and had

287 The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9- through 26-year-

288 Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccina

289 after a single dose of 2-valent or 9-valent HPV vaccine were comparable to those in young women who

290 r years postvaccination, 2 doses of bivalent HPV vaccine were effective in the prevention of incident

291 oses (at 0, 1, and 6 months) of the bivalent HPV vaccine were identified in the vaccination registrat

292 participants who received one dose of either HPV vaccine were seropositive for HPV 16 IgG antibodies,

293 Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a

294 Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and

295 A single dose of HPV vaccine, when given to girls in the target age range

296 ection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against H

297 or HPV-6/11 infection with the quadrivalent HPV vaccine will result in a high neutralizing antibody

298 e decentralised with the hope that effective HPV vaccines will be made increasingly available in low-

299 funded and initiated before licensure of the HPV vaccines), with the aim of assessing the efficacy of

300 re widespread availability of a prophylactic HPV vaccine would be useful.